Drug intelligence / Profile preview

lunasin

Development stage
Discontinued
Lead developer
Reliv
Modality
Peptides
Administration
Oral
01

Overview

Lunasin is a naturally occurring peptide first isolated from soybeans, also found in barley and rye. [4, 15] It was investigated as a potential treatment for Amyotrophic Lateral Sclerosis (ALS) based on a media report of a single patient experiencing a dramatic symptom reversal and preclinical data suggesting it could alter histone acetylation patterns, which are abnormal in ALS patients. [2] However, a subsequent 12-month, open-label clinical trial (NCT02709330) in 50 patients with ALS found no evidence that lunasin slowed, stopped, or reversed disease progression. [2, 5, 8] The study also failed to demonstrate a significant effect on the proposed mechanism of histone H3 or H4 acetylation in blood samples. [2, 8] The treatment was associated with gastrointestinal side effects, most commonly constipation, and two serious cases of obstipation/fecal impaction requiring hospitalization were possibly related to the treatment. [2, 5] Lunasin has also been researched for its potential anti-inflammatory, antioxidant, and chemopreventive properties. [1, 3, 10]

Brand names
LunaRich X
Other names
LunasinLunarich X
02

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)H3 (Histone H3.2)FOS (Activator Protein 1)CCND1 (Cyclin D1)H4 (Extracellular Histone H4)

Beyond the preview

Go deeper on lunasin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lunasin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call